STOCK TITAN

Stemtech Corporation on Track for CEO and Chairman's Goal for Growth and Global Expansion

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Stemtech is making significant strides towards achieving its CEO and Chairman's goal of becoming cash flow positive. The company is focusing on revenue growth in existing countries and expanding into new markets, experiencing success with growth in revenue, new product offerings, and expansion into African and Western European countries. Stemtech's recognition in the top 5% of direct selling companies by 'Business for Home' underlines its position as a key player in the industry. The company's leadership emphasizes the growing demand for its products and the need for capital to support its expanding business.
Stemtech sta compiendo progressi significativi verso l'obiettivo del suo CEO e Presidente di diventare un'azienda con flussi di cassa positivi. La compagnia si sta concentrando sulla crescita dei ricavi nei paesi in cui è già presente e sull'espansione in nuovi mercati, ottenendo successo nell'incremento dei ricavi, nell'offerta di nuovi prodotti e nell'espansione in paesi africani e dell'Europa occidentale. Il riconoscimento di Stemtech tra il top 5% delle aziende di vendita diretta da parte di 'Business for Home' sottolinea la sua posizione come attore chiave nel settore. La leadership dell'azienda enfatizza la crescente domanda per i suoi prodotti e la necessità di capitale per supportare la sua espansione.
Stemtech está logrando avances significativos hacia la meta de su CEO y Presidente de alcanzar un flujo de caja positivo. La empresa se enfoca en el crecimiento de ingresos en los países donde ya opera y en la expansión a nuevos mercados, experimentando éxito en el aumento de ingresos, la oferta de nuevos productos y la expansión a países de África y Europa Occidental. El reconocimiento de Stemtech entre el top 5% de las empresas de venta directa por 'Business for Home' destaca su posición como un jugador clave en la industria. La dirección de la compañía enfatiza la creciente demanda de sus productos y la necesidad de capital para apoyar su expansión empresarial.
Stemtech는 CEO 및 회장의 현금 흐름 긍정적 목표를 달성하기 위해 중요한 진전을 이루고 있습니다. 이 회사는 기존 국가에서의 수익 성장과 새로운 시장으로의 확장에 초점을 맞추며, 수익 증가, 새로운 제품 제공, 아프리카 및 서유럽 국가로의 확장에서 성공을 경험하고 있습니다. 'Business for Home'에 의한 직접 판매 회사 상위 5%로서 Stemtech의 인정은 업계에서 핵심 플레이어로서의 위치를 강조합니다. 회사의 리더십은 제품에 대한 수요가 증가하고 있음을 강조하고 비즈니스 확장을 지원하기 위한 자본의 필요성을 강조합니다.
Stemtech réalise des progrès significatifs vers l'objectif de son PDG et Président de devenir positif en termes de flux de trésorerie. L'entreprise se concentre sur la croissance des revenus dans les pays existants et l'expansion dans de nouveaux marchés, connaissant un succès dans l'augmentation des revenus, l'offre de nouveaux produits et l'expansion dans les pays africains et d'Europe occidentale. La reconnaissance de Stemtech parmi les 5% meilleures entreprises de vente directe par 'Business for Home' souligne sa position en tant qu'acteur clé de l'industrie. Les dirigeants de l'entreprise mettent en avant la demande croissante pour ses produits et la nécessité de capitaux pour soutenir son expansion commerciale.
Stemtech macht bedeutende Fortschritte bei der Erreichung des Ziels seines CEO und Vorsitzenden, einen positiven Cashflow zu erzielen. Das Unternehmen konzentriert sich auf Umsatzwachstum in bestehenden Ländern und die Expansion in neue Märkte, erzielt Erfolge beim Umsatzwachstum, neuen Produktangeboten und der Expansion in afrikanische und westeuropäische Länder. Die Anerkennung von Stemtech als eine der Top 5% der Direktvertriebsunternehmen durch 'Business for Home' unterstreicht seine Position als Schlüsselakteur in der Branche. Die Unternehmensführung betont die wachsende Nachfrage nach ihren Produkten und den Kapitalbedarf zur Unterstützung ihrer Geschäftsexpansion.
Positive
  • Stemtech is experiencing growth in revenue and expanding into new markets in Africa and Western Europe.
  • The company's recognition in the top 5% of direct selling companies by 'Business for Home' highlights its industry position.
  • Stemtech's leadership emphasizes the demand for its products and the need for capital to support business expansion.
Negative
  • None.

Industry Recognition: Stemtech Ranked Top 5% in Direct Selling by 'Business for Home'"

NAPLES, FL / ACCESSWIRE / April 19, 2024 / (OTCQB:STEK)

Stemtech Corporation, a leader in innovative health and wellness solutions through stem cells technology, is proud to announce that it is on track to achieve the CEO and Chairman's goal of becoming cash flow positive. With a focus on revenue growth in existing countries and expansion into new markets, Stemtech is experiencing success.

Over the past year, Stemtech has seen growth in revenue, driven by a strategic emphasis on recruiting Independent Business Partners (IBPs), customers and expanding product offerings. The company's products are now available for sale in several new African countries, including Kenya, Nigeria, Uganda, and the Democratic Republic of Congo, through a third-party distributor with orders already shipped. . Additionally, Stemtech has secured agreements to introduce its products in several Western European countries, with orders soon to come.

"These developments mark significant milestones for Stemtech as we continue our journey towards global expansion," said Charles S. Arnold, CEO and Chairman of Stemtech. "The demand for our products is surging and our presence in these new markets reflects the growing recognition of the health benefits our Stem Cell solutions offer."

Stemtech's achievements are further underscored by its recognition in the industry. Stemtech has been ranked in the top 5% of approximately 700 companies on "Business for Home" (https://www.businessforhome.org/momentum-ranks/) the leading industry publication, which evaluates companies in the direct selling industry. This recognition highlights Stemtech's position as a key player in the market and reflects the company's commitment to excellence and innovation. We are proud that Stemtech has been recognized frequently in this prestigious publication.

"Stemtech is at a pivotal moment in our growth trajectory," added John W. Meyer President and COO. "Our explosive growth and increasing notoriety are a testament to the quality and effectiveness of our products and our business income-earning opportunity which our products have proffered for nearly 19 years. The key now is to have access to the capital necessary to provide the inventory for our expanding number of IBPs and customers. We are excited about the future and remain dedicated to empowering individuals worldwide to achieve their health, wealth and financial independence goals".

ABOUT STEMTECH
Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (OTCQB: STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech products. Stemtech is well positioned as the pioneer in stem cell nutrition, oral and skin care products, to increase sales in the wellness industry.

FORWARD LOOKING STATEMENTS
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on December 1, 2023. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

Investor Relations:
Gabriel Rodriguez
Email: erelationsgroup@gmail.com
Phone: +1 623-261-9046

Stemtech Corporation
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com

SOURCE: Stemtech Corporation



View the original press release on accesswire.com

FAQ

What is Stemtech 's current goal?

Stemtech is on track to achieve the CEO and Chairman's goal of becoming cash flow positive.

In which countries has Stemtech expanded its product offerings?

Stemtech has expanded its product offerings into new African countries such as Kenya, Nigeria, Uganda, and the Democratic Republic of Congo, as well as securing agreements to introduce products in several Western European countries.

How has Stemtech been recognized in the industry?

Stemtech has been ranked in the top 5% of direct selling companies by 'Business for Home', highlighting its position as a key player in the industry.

What is the key focus for Stemtech's growth trajectory according to John W. Meyer?

John W. Meyer, Stemtech's President and COO, emphasizes the need for access to capital to provide inventory for the company's expanding number of IBPs and customers.

STEMTECH CORP

OTC:STEK

STEK Rankings

STEK Latest News

STEK Stock Data

6.74M
92.19M
31.59%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Naples